• Thomas O Bergmeijer, JanssenPaul W APWDepartment of Cardiology, St Antonius Hospital, Nieuwegein, The Netherlands., Jurjan C Schipper, Khalid Qaderdan, Maycel Ishak, Rianne S Ruitenbeek, Folkert W Asselbergs, Arnoud W J van 't Hof, Willem J M Dewilde, Fabrizio Spanó, HerrmanJean-Paul RJPDepartment of Cardiology, Onze Lieve Vrouwe Gasthuis, Amsterdam, The Netherlands., Johannes C Kelder, Maarten J Postma, Anthonius de Boer, Vera H M Deneer, and Jurriën M ten Berg.
• Department of Cardiology, St Antonius Hospital, Nieuwegein, The Netherlands. Electronic address: jurtenberg@gmail.com.
• Am. Heart J. 2014 Jul 1; 168 (1): 16-22.e1.

RationaleIn patients with ST-segment elevation myocardial infarction (STEMI) who undergo primary percutaneous coronary intervention (pPCI), the use of dual antiplatelet therapy is essential to prevent atherothrombotic complications. Therefore, patients are treated with acetylsalicylic acid and clopidogrel, prasugrel, or ticagrelor. Clopidogrel, however, shows a major interindividual variation in antiplatelet effect, which is correlated to an increase in atherothrombotic events in patients with high platelet reactivity. This interindividual variation is partly a result of CYP2C19 genetic variants. Ticagrelor and prasugrel reduce atherothrombotic events but increase bleeding rate and drug costs, as compared with clopidogrel. CYP2C19-based tailoring of antiplatelet therapy might be beneficial to STEMI patients.Study DesignPOPular Genetics (NCT01761786) is a randomized, open-label, multicenter trial involving 2,700 STEMI patients who undergo pPCI. Patients are randomized to CYP2C19 genotyping or routine ticagrelor or prasugrel treatment. In the genotyping group, *1/*1 (wild-type) patients receive clopidogrel, and patients carrying 1 or 2 *2 or *3 loss-of-function alleles receive ticagrelor or prasugrel. The primary net clinical benefit end point is the composite of death, (recurrent) myocardial infarction, definite stent thrombosis, stroke, and Platelet Inhibition and Patient Outcomes (PLATO) major bleeding at 1 year. Primary safety end point is the composite of (PLATO) major and minor bleeding. Cost-effectiveness and quality of life will be assessed by calculating quality-adjusted life-years, net costs per life-year, and per quality-adjusted life-year gained.ConclusionThe POPular Genetics study is the first large-scale trial comparing CYP2C19 genotype-guided antiplatelet therapy to a nontailored strategy in terms of net clinical benefit, safety, and cost-effectiveness.© 2014.

28 keywords...

hide…